{"filing":{"accession_number":"0001193125-26-239246","cik":"0001590750","ticker":"VRDN","company_name":"Viridian Therapeutics, Inc.\\DE","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"d111034d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526239246/d111034d8k.htm"},"events":[{"id":9027,"run_id":7924,"accession_number":"0001193125-26-239246","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Viridian entered into a Commercial Manufacturing Services Agreement with WuXi Biologics on May 24, 2026, for long-term supply of veligrotug drug substance and product for commercial use. While this is a manufacturing/supply agreement rather than a traditional M\u0026A transaction, it constitutes a material definitive agreement under Item 1.01 that secures critical commercial supply infrastructure for the Company's lead product contingent on regulatory approval. The five-year initial term with automatic renewal, volume-based pricing, and binding commitments make this a material commercial arrangement that would affect investor assessment of the Company's commercialization readiness and operational risk.","company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1506,"accession_number":"0001193125-26-239246","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Viridian entered into a Commercial Manufacturing Services Agreement with WuXi Biologics on May 24, 2026, for long-term supply of veligrotug drug substance and product for commercial use. While this is a manufacturing/supply agreement rather than a traditional M\u0026A transaction, it constitutes a material definitive agreement under Item 1.01 that secures critical commercial supply infrastructure for the Company's lead product contingent on regulatory approval. The five-year initial term with automatic renewal, volume-based pricing, and binding commitments make this a material commercial arrangement that would affect investor assessment of the Company's commercialization readiness and operational risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:11:37.637605+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1506,"accession_number":"0001193125-26-239246","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Viridian entered into a Commercial Manufacturing Services Agreement with WuXi Biologics on May 24, 2026, for long-term supply of veligrotug drug substance and product for commercial use. While this is a manufacturing/supply agreement rather than a traditional M\u0026A transaction, it constitutes a material definitive agreement under Item 1.01 that secures critical commercial supply infrastructure for the Company's lead product contingent on regulatory approval. The five-year initial term with automatic renewal, volume-based pricing, and binding commitments make this a material commercial arrangement that would affect investor assessment of the Company's commercialization readiness and operational risk.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:11:37.637605+00:00","company_name":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","filing_date":"2026-05-26"}]}